Sample size determination with familywise control of both type I and type II errors in clinical trials

被引:2
作者
Wang, Bushi [1 ]
Ting, Naitee [1 ]
机构
[1] Boehringer Ingelheim Pharmaceut Inc, Biostat & Data Sci, 900 Ridgebury Rd, Ridgefield, CT 06877 USA
关键词
Complete power; familywise error rate; minimal power; optimal Bonferroni plus procedure; r-power; sample size determination; type I error; type II error; PRIMARY END-POINTS; STEP-DOWN; TESTING PROCEDURES; MULTIPLE TESTS;
D O I
10.1080/10543406.2016.1148706
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The concept of controlling familywise type I and type II errors at the same time is essentially an integrated process to deal with multiplicity issues in clinical trials. The process will select a multiple testing procedure (MTP) which controls the familywise type I error and calculate the per hypothesis sample size such that the studywise power is maintained at desired level. The power of a study can be defined in several ways and it depends on the objective. In this article, we provide general guidance on how to make the selection of MTPs and calculate sample size simultaneously. We introduce the concept of strong and weak control of the familywise type II error and generalized familywise type II error. We also proposed the novel Bonferroni+ and optimal Bonferroni+ procedures to allocate per hypothesis type II error. We demonstrated the value of the proposed work as it cannot be replaced by simple simulations. A real clinical trial is discussed throughout the article as an example.
引用
收藏
页码:951 / 965
页数:15
相关论文
共 20 条
[1]   Sample size calculation for simulation-based multiple-testing procedures [J].
Bang, HJ ;
Jung, SH ;
George, SL .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2005, 15 (06) :957-967
[2]   MULTI-PARAMETER HYPOTHESIS-TESTING AND ACCEPTANCE SAMPLING [J].
BERGER, RL .
TECHNOMETRICS, 1982, 24 (04) :295-300
[3]   On power and sample size computation for multiple testing procedures [J].
Chen, Jie ;
Luo, Jianfeng ;
Liu, Kenneth ;
Mehrotra, Devan V. .
COMPUTATIONAL STATISTICS & DATA ANALYSIS, 2011, 55 (01) :110-122
[4]  
Committee for Proprietary Medicinal Products (CPMP), 2002, POINTS CONS MULT ISS
[5]   A STEP-UP MULTIPLE TEST PROCEDURE [J].
DUNNETT, CW ;
TAMHANE, AC .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1992, 87 (417) :162-170
[6]   STEP-UP MULTIPLE TESTING OF PARAMETERS WITH UNEQUALLY CORRELATED ESTIMATES [J].
DUNNETT, CW ;
TAMHANE, AC .
BIOMETRICS, 1995, 51 (01) :217-227
[7]   Sample size determination in step-down and step-up multiple tests for comparing treatments with a control [J].
Dunnett, CW ;
Horn, M ;
Vollandt, R .
JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 2001, 97 (02) :367-384
[8]   COMPARISONS BETWEEN A NEW DRUG AND ACTIVE AND PLACEBO CONTROLS IN AN EFFICACY CLINICAL-TRIAL [J].
DUNNETT, CW ;
TAMHANE, AC .
STATISTICS IN MEDICINE, 1992, 11 (08) :1057-1063
[9]   On a multiple endpoints testing problem [J].
Eaton, Morris L. ;
Muirhead, Robb J. .
JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 2007, 137 (11) :3416-3429
[10]  
European Medicines Agency, 2007, MAC EUR PUBL ASS REP